Prosight Management, LP Cytom X Therapeutics, Inc. Transaction History
Prosight Management, LP
- $378 Million
- Q3 2025
A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 564,800 shares of CTMX stock, worth $2.18 Million. This represents 0.48% of its overall portfolio holdings.
Number of Shares
564,800
Previous 3,517,113
83.94%
Holding current value
$2.18 Million
Previous $7.98 Million
77.44%
% of portfolio
0.48%
Previous 2.16%
Shares
5 transactions
Others Institutions Holding CTMX
# of Institutions
109Shares Held
121MCall Options Held
1.49MPut Options Held
258K-
Vr Adviser, LLC New York, NY15.6MShares$60.1 Million7.54% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$42.7 Million1.6% of portfolio
-
Perceptive Advisors LLC New York, NY9.68MShares$37.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$34.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$32.7 Million0.92% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $255M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...